Respirerx Pharma - RSPI STOCK NEWS

Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.

RESPIRERX PHARMA INC (RSPI) is a pharmaceutical company focused on developing innovative treatments for various respiratory disorders and neurological conditions. The company's core business revolves around the research and development of therapeutic solutions that target specific neurotransmitter pathways to address unmet medical needs.

RESPIRERX PHARMA INC has recently made significant strides in advancing its lead product candidates, including ResolutionRx, a novel pharmaceutical cannabinoid being developed to treat respiratory conditions, and EndeavourRx, a cutting-edge neuromodulator designed to address neurological disorders. The company's financial condition remains robust, supported by strategic partnerships and a pipeline of promising products in various stages of development.

02/10/2025 07:00 AM

News

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

Rhea-AI Summary

RespireRx Pharmaceuticals has issued a stockholder letter highlighting its 2024 progress and 2025 outlook. The company reported fourteen peer-reviewed publications in 2024, with two additional papers published in 2025. Their collaborator, Shirley Ryan AbilityLab, received a $1.8 million DoD grant for Phase 2A and 2B clinical trials testing CX1739 in spinal cord injured patients.

The company faces several challenges, including non-compliance with SEC reporting requirements, insufficient available common stock shares, and difficulties implementing the DoD grant. To address these issues, RespireRx has established two subsidiaries: ResolutionRx in Australia for cannabinoid program development, and EndeavourRx for neuromodulator programs.

The company has amended its preferred stock certificates to enable capital raising and is pursuing strategic collaborations, research partnerships, and grant opportunities. A high-scoring SBIR grant application for their GABAkines program is under review.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

05/29/2024 08:15 AM

News

RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury

Rhea-AI Summary

RespireRx Pharmaceuticals announced a $1.8 million award from the Department of Defense (DOD) to fund Phase 2 clinical trials for CX1739, their lead AMPAkine, aimed at improving bladder function in patients with spinal cord injury (SCI). Conducted by Shirley Ryan AbilityLab and led by Dr. Milap Sandhu, the study will have two stages: Phase 2A for single dose safety and efficacy, and Phase 2B for placebo-controlled trials. RespireRx has been allocated $252,200 for manufacturing and regulatory submissions. Clinical trials are projected to begin by Q4 2024. CX1739 has previously shown promising results in preclinical animal studies and early human trials.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

575%

Tags

03/20/2024 08:30 AM

News

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

Rhea-AI Summary

RespireRx Pharmaceuticals Inc. announces positive results from a research article on CX1739's ability to restore bladder function in rodents with spinal cord injury. The study highlights the potential of this AMPAkine to address neurogenic bladder dysfunction, improving patients' quality of life.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

25%

Tags

02/13/2024 08:30 AM

News

RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

Rhea-AI Summary

RespireRx Pharmaceuticals Inc. announces the advancement of KRM-II-81, a GABAA receptor potentiator, within the NIH HEAL Initiative's Preclinical Screening Platform for Pain program. The compound shows promising results in blocking pain-like behaviors in rats without detectable side effects, supporting its efficacy in various pain models.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.14%

Tags

01/22/2024 08:30 AM

News

RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

Rhea-AI Summary

RespireRx Pharmaceuticals Inc. appoints Dr. Dariusz Nasiek MD, MBA to its board of directors. Dr. Nasiek is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management. He brings considerable value with his clinical experience in the areas in which RespireRx is developing its compounds for the treatment of respiratory disorders and spinal injury with the AMPAkine platform, and the development of GABAkines for use as non-narcotic analgesics and for treatment-resistant epilepsy.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

53.85%

Tags

01/04/2024 08:45 AM

News

RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient

Rhea-AI Summary

RespireRx Pharmaceuticals Inc. (RSPI) reports successful suppression of epileptiform activity in a 19-year-old patient with pharmaco-resistant epilepsy using KRM-II-81, a novel GABAkine. The findings, published in Heliyon, Cell Press's peer-reviewed journal, suggest potential success in reducing seizure burden in pharmaco-resistant patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

11.11%

Tags

12/11/2023 08:30 AM

News

RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development

Rhea-AI Summary

RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) has announced an agreement with Ponto Ventures LLC for Will Clodfelter to serve as Senior Vice President of Business Development on a part-time basis. Mr. Clodfelter will lead business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company. He has extensive experience in business development, strategy, and valuation consulting services to pharmaceutical, biotech, and medical device companies, with over 30 international and domestic pharmaceutical licensing and device negotiations. Mr. Clodfelter previously held positions at Eli Lilly and Co. and Amylin Pharmaceuticals, and was the Chief Executive Officer of Medicus Biosciences and Abvance Therapeutics, both biotechnology firms based in California.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-20%

Tags

10/12/2023 08:45 AM

News

RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services

Rhea-AI Summary

RespireRx and ResolutionRx announce partnership with Ab Initio Pharma for manufacturing and testing therapeutic drugs based on lipid nanoparticle technology

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

08/09/2023 08:50 AM

News

RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

25%

Tags

05/24/2023 08:30 AM

News

ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

Rhea-AI Summary

RespireRx and ResolutionRx have entered into a Letter of Intent with Cantheon Capital for an aggregate investment of $3,125,000 in Australian Series A Preference Shares. The investment will support clinical trial research and development over a two and a half year period. The Series A Shares are convertible and subject to a mandatory and automatic conversion feature. RespireRx expects to incur R&D costs of approximately $16,530,571. The Ordinary Shares will be listed for trading on the Australian Securities Exchange within eighteen months.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.5%

Tags

FAQ

What is the current stock price of Respirerx Pharma (RSPI)?

The current stock price of Respirerx Pharma (RSPI) is $0.0024 as of February 28, 2025.

What is the market cap of Respirerx Pharma (RSPI)?

The market cap of Respirerx Pharma (RSPI) is approximately 377.4K.

What is the primary focus of RESPIRERX PHARMA INC?

RESPIRERX PHARMA INC is primarily focused on developing innovative treatments for respiratory disorders and neurological conditions.

What are some of the lead product candidates of RESPIRERX PHARMA INC?

RESPIRERX PHARMA INC's lead product candidates include ResolutionRx, a pharmaceutical cannabinoid for respiratory conditions, and EndeavourRx, a neuromodulator for neurological disorders.

Where is RESPIRERX PHARMA INC headquartered?

RESPIRERX PHARMA INC is headquartered at 126 Valley Road, Suite C, Glen Rock, NJ 07452.

How can I contact Jeff Margolis of RESPIRERX PHARMA INC?

You can reach Jeff Margolis, Senior Vice President, Chief Financial Officer, Treasurer, and Secretary of RESPIRERX PHARMA INC, at 917-834-7206 or jmargolis@respirerx.com.